Geron Community
NasdaqGS:GERN Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 20 Fair Values set on narratives written by author
Community Investing Ideas
WA
Community Contributor
Geron Will Benefit from European Approval of RYTELO in Myelodysplastic Syndromes
Geron Corporation has announced that the European Commission has granted marketing authorization for RYTELO (imetelstat) as a monotherapy for the treatment of adult patients with transfusion-dependent anemia due to lower-risk myelodysplastic syndromes (LR-MDS). Key Highlights: - RYTELO is the first and only telomerase inhibitor approved in the U.S. and Europe for LR-MDS.
View narrativeUS$2.42
FV
38.8% undervalued intrinsic discount98.00%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
20 days ago author updated this narrative